India starts hearing Bayer's appeal in Nexavar compulsory licensing case
This article was originally published in Scrip
Executive Summary
India's Intellectual Property Appellate Board (IPAB) has begun hearing Bayer's appeal in the crucial case concerning the compulsory licence granted for its anticancer Nexavar (sorafenib tosylate) to the domestic firm, Natco Pharma.